Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical TrialCOVID-19로 입원한 환자의 14일째 임상 상태에 대한 하이드록시클로로퀸의 효과: 무작위 임상 시험Randomized Controlled Trial Published on 2020-12-012022-09-25 Journal: JAMA [Category] 임상, 진단, 치료제, [키워드] 28-day mortality 7-category ordinal scale absolute difference activities acute respiratory syndrome adjusted odds ratio Adults adults hospitalized analyzed assigned blinded clinical clinical status conducted coronavirus coronavirus disease COVID-19 Day death determine died discharged doses duration of symptom Effect Efficacy enrolled extracorporeal membrane oxygenation greater groups hospital Hospitalized Hydroxychloroquine hydroxychloroquine group IMPROVE Infection intensive care interim analysis interquartile range Invasive mechanical ventilation median median age multicenter multivariable nasal Noninvasive ventilation outcome Patient patients Placebo placebo group placebo-controlled randomized trial positive Primary outcome randomization Randomized Randomly receiving Respiratory illness respiratory symptom Sample size secondary outcome Secondary outcomes significantly status supplemental oxygen Support the placebo group Treatment Trial use of hydroxychloroquine with COVID-19 [DOI] 10.1001/jama.2020.22240 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and efficacy of herbal extracts to restore respiratory health and improve innate immunity in COVID-19 positive patients with mild to moderate severity: A structured summary of a study protocol for a randomised controlled trialLetter Published on 2020-11-232022-10-29 Journal: Trials [Category] COVID-19, SARS, [키워드] 1:1 administer Administered allergic Analysis Asparagus automatically Ayurveda CAM CAP Capsule clinical coded COVID COVID 19 COVID-19 COVID-19 positive patient CTRI Date declining dissemination Dizziness dose double blind drop-outs early recovery Efficacy element eligible Embelia enrolled enrolment exploratory Follow-up function ginger glycyrrhiza Health health condition Herbal Herbo-mineral IL6 IMPROVE in viral India Infection Innate immunity Intervention intervention group investigator Last Medicine Memorial Mild moderate number objective outcome parallel group participant Patient patients with COVID-19 positive positive patient positive RT-PCR product protocol racemosus randomised randomised controlled trial Randomized Rash recruitment reducing Registered registration number registry Safe Safety Sample size screened secondary Shankha status study period Study protocol submission Test Th17 the disease the placebo group Treatment Trial two group two groups Viral load website were blinded Zinc Zingiber [DOI] 10.1186/s13063-020-04906-x PMC 바로가기 [Article Type] Letter
The clinical effect of Nano micelles containing curcumin as a therapeutic supplement in patients with COVID-19 and the immune responses balance changes following treatment: A structured summary of a study protocol for a randomised controlled trialCOVID-19 환자의 치료 보조제로 커큐민을 함유한 나노 미셀의 임상 효과 및 치료 후 면역 반응 균형 변화: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-10-222022-08-13 Journal: Trials [Category] MERS, SARS, 임상, [키워드] 1:1 accompany addition allergy assigned balance Bandar Abbas bedtime blind Blinding both groups breakfast Capsule change Characteristics chronic chronic obstructive pulmonary disease clinical Clinical effect clinical examination clinical examinations clinical symptom clinical trial clinical trials Comorbidities Comorbidity company comparator Complete computer conducted congestive heart failure control group COVID-19 COVID-19 patient COVID-19 patients Curcumin Cytokines digit digits dinner dissemination Effectiveness element evaluate evaluated expected expression filtration filtration rate FOXP3 gallstone gastritis GATA Gender Gene Expression glomerular filtration rate heart failure history IFN-γ IL-17 IL-4 immune response immune responses in both group inclusion criteria Inflammatory marker inflammatory markers information Interleukins intervention group Iran kPa Laboratory laboratory findings laboratory technician laboratory technicians lactation less liver liver failure Lymphocytes number Nurses objective Obstructive obstructive pulmonary disease outcome PaO2 parallel group participant Participation Patient patients patients with COVID-19 per day performed Peripheral blood physician Placebo placebo group placebo-controlled positive COVID-19 post treatment Pregnancy protocol pulmonary disease random randomisation randomised randomised controlled trial randomization Randomized randomized clinical trial Randomly real time PCR recorded recruitment Registered registry Regulatory renal renal failure routine standard treatment Sample size sealed selected serum cytokine serum cytokines Serum level serum parameter serum parameters shift single-center statisticians Study protocol T helper TGF-β the placebo group therapeutic Treatment Trial Trial registration ventilator Version website written consent [DOI] 10.1186/s13063-020-04824-y PMC 바로가기 [Article Type] Letter
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyHIV에 감염되지 않은 건강한 성인을 대상으로 한 두 가지 이종 HIV 백신 요법의 안전성 및 면역원성(TRAVERSE): 무작위 배정, 병렬 그룹, 위약 대조, 이중 맹검, 1/2a상 연구Articles Published on 2020-09-302022-09-06 Journal: The Lancet. HIV [Category] Communicable Disease, [키워드] 95% CI Ad26 Adenovirus Administered advancement adverse event adverse events aligned All participant All participants Analysis Antigen antigens applied assigned binding antibodies binding antibody blood sample breadth CD4+ T-cell clade collected computer-generated Defense Deltoid muscle Department diagnosed dose double-blind Efficacy elicit Eligible participants ELISpot responses enrolled finding first vaccination foundation funding group groups healthy Heterologous HIV HIV infection HIV vaccine HIV-1 infection HIV-uninfected IFNγ ELISPOT response IFNγ ELISPOT responses IgG immune response immune responses Immunity immunogenicity injection Intramuscular injection investigator investigators Jackson janssen Laboratory Local magnitude median medical history Medicine Melinda Gate Melinda Gates Military Medicine mononuclear cell mononuclear cells opinion Other parallel-group participant PBMC PBMCs per protocol per-protocol Peripheral blood Peripheral blood mononuclear cells Physical examination Placebo placebo group placebo-controlled placebos prevention randomisation randomised Randomly randomly permuted block randomly permuted blocks regimen regimens Registered repeated risk Safe Safety second vaccination Sponsor stratified subgroups systemic reactogenicity T-cell Response tested tetravalent the placebo group titre titres Tolerability treatment allocation Trial trivalent USA vaccination vaccination schedule Vaccinations Vaccine vaccine group vectored vaccine vital sign was done with HIV [DOI] 10.1016/S2352-3018(20)30229-0 PMC 바로가기 [Article Type] Articles
Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trialLetter Published on 2020-07-292022-10-29 Journal: Trials [Category] COVID-19, SARS, [키워드] 1:1 acute respiratory syndrome Adults adverse event antiretroviral Antiviral Arm Barcelona blinded Blood Breastfeeding Chloroquine condition confirmed case confirmed COVID-19 case Contact Control control group Controlled clinical trial coronavirus coronavirus disease Corticosteroid COVID-19 declining defined develop disease dissemination double-blind double-blinded Efficacy element eligibility Epidemic equipment evaluate Follow-up group healthcare worker Healthcare workers high risk hospital Hydroxychloroquine hydroxychloroquine treatment identify incidence Infection Intervention intervention group investigator marker multicentre National number Nurse objective Occurrence Older outcome participant Participants PCR physical Placebo placebo tablet polymerase chain positive PCR PPE pre-exposure predict predictor Pregnancy primary endpoint Prophylaxis protocol random randomisation randomised randomised controlled trial Randomized Randomized controlled trial Rapid diagnostic test RDT reached receive recruited reducing Registered Repository Research risk Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR Secondary endpoints Seroconversion serological serology serum sample Spain Spanish Standard of care status Study protocol Symptom Tablet the placebo group the SARS-CoV-2 Treatment Trial website with COVID-19 [DOI] 10.1186/s13063-020-04621-7 PMC 바로가기 [Article Type] Letter
Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial비경구 3가 P2-VP8 소단위 로타바이러스 백신의 안전성 및 면역원성: 다중 부위, 무작위, 이중 맹검, 위약 대조 시험Article Published on 2020-07-012022-09-06 Journal: The Lancet. Infectious Diseases [Category] Communicable Disease, [키워드] adjusted Adults adverse event adverse events African age All participants analysed Antigen assigned baseline block block size block sizes blocks blood sample Blood samples Comparisons death Deltoid muscle dose dose-escalation double-blind Efficacy elicited eligible enrolment evaluate febrile febrile convulsion Final finding FIVE foundation funding geometric mean geometric mean titre gestation GRADE group groups HIV infection IgA IgG IgG seroresponse IgG seroresponses immunogenic immunogenicity immunogenicity endpoint Infant Infants injection Injections Intramuscular injection Laboratory Local Melinda Gate Melinda Gates Meningitis multisite neutralising antibody neutralising antibody response Neutralising antibody responses neutralising antibody seroresponse neutralising antibody seroresponses no significant difference no significant differences occurred parent parents participant Participants Placebo placebo group placebo recipient placebo recipients placebo-controlled placebo-controlled trial pneumococcal pneumococcal meningitis protocol randomisation randomised Randomly receive recipient Registered Research respiratory Respiratory tract infections response responses against rotavirus vaccination rotavirus vaccine Safety safety endpoint Serious Adverse Event Serious Adverse Events serum significantly higher South South Africa Strains subunit Support systemic adverse events systemic reaction systemic reactions the placebo group the vaccine timepoints Treatment Trial trivalent USA Vaccine was done were assessed [DOI] 10.1016/S1473-3099(20)30001-3 PMC 바로가기 [Article Type] Article
Two Randomized Controlled Trials of Bacillus Calmette-Guérin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trialsLetter Published on 2020-06-052022-10-29 Journal: Trials [Category] Coronavirus, SARS, [키워드] 1:1 ambulance service assistant Bacillus BCG BCG vaccination BCG-vaccine blinded Care Community Controlled COVID-19 COVID-19 infection COVID-19 pandemic cumulative Denmark dissemination elderly element facilitate HCW HCWs Health care Health care worker Health-care workers hospital Hospital admission hospitals incidence Intervention intervention group investigators Medicine NaCl Netherlands number objective outcome outcome assessor parallel group participant Patient physician Placebo placebo group placebo-controlled protocol randomised randomised controlled trial Randomized randomized trial recruitment reduce Registered registry Research Sample size status stratified Study protocol the placebo group Trial vaccination Vaccine website [DOI] 10.1186/s13063-020-04389-w PMC 바로가기 [Article Type] Letter
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial중증 COVID-19 성인에 대한 렘데시비르: 무작위, 이중 맹검, 위약 대조, 다기관 시험Randomized Controlled Trial Published on 2020-05-162022-09-11 Journal: Lancet (London, England) [Category] SARS, 비임상, [키워드] Academy acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adult patients Adverse adverse event adverse events Analysis animal models antiviral drug arterial oxygen partial pressure assigned Beijing breath China Chinese clinical benefits Clinical improvement clinical status concomitant use confirmation coronavirus coronavirus disease Coronavirus disease 2019 Corticosteroids COVID-19 defined development discharged double-blind effective Eligible patients Emergency enrolled enrolment event faster followed by fractional inspired oxygen GS-5734 hazard ratio hospital human coronaviruses in vitro inhibit inhibitory effect Inhibitory effects intention-to-treat interferons Intravenous remdesivir ITT ITT population laboratory-confirmed SARS-CoV-2 infection less Lopinavir Lopinavir-ritonavir Medical Science Middle East Middle East respiratory syndrome Middle East respiratory syndrome Coronavirus multicentre nucleoside one patient Ordinal Scale oxygen oxygen partial pressure oxygen saturation partial pressure pathogenic Patient Placebo placebo group placebo recipients placebo-controlled Pneumonia primary analysis primary endpoint Program randomisation randomised Randomly receiving recipient reduction in Registered Remdesivir reported research and development respiratory respiratory syndrome coronavirus Ritonavir room air safety analysis SARS-CoV-1 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication Science severe acute respiratory syndrome Coronavirus severe coronavirus disease severe COVID-19 statistically significant symptom duration symptom onset technology the placebo group those receiving placebo treated Treatment treatment group Trial Volume was done [DOI] 10.1016/S0140-6736(20)31022-9 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trialDNA 또는 NYVAC 벡터(HVTN 096)가 있는 외피 단백질을 포함하는 다가 HIV 백신의 안전성 및 면역원성: 1b상, 이중 맹검, 위약 대조 시험Article Published on 2019-10-072022-09-06 Journal: The Lancet. HIV [Category] Communicable Disease, [키워드] active treatment Administered administration adverse event allergy antibodies antibody Antibody Response Antibody responses antibody-dependent cell-mediated cytotoxicity approach assigned binding binding antibody boost Cell-mediated cytotoxicity Combination component computer-generated Coverage cranial cytotoxicity died DNA dose doses double-blind early administration effective Efficacy enrolled envelope protein epitope finding followed by foundation funding glycoprotein gp120 healthy healthy volunteer healthy volunteers HIV infection HIV vaccine IgG IgG response IgG responses immunogenicity individual Infection Infectious diseases injection Lymphadenopathy marker measure Melinda Gate Melinda Gates motor vehicle Neutralising Antibodies outcome participant Participants Placebo placebo group placebo-controlled placebo-controlled trial Primary outcomes priming product Protein purified random Randomly reactogenicity regimen Registered responses risk Safety screened Serious Adverse Event Serious Adverse Events Switzerland the placebo group the vaccine trauma Treatment treatment group treatment groups Trial trials vaccination vaccination schedule Vaccinations Vaccine vector Volunteer [DOI] 10.1016/S2352-3018(19)30262-0 PMC 바로가기 [Article Type] Article
Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM 197 -Conjugate Vaccine During Pregnancy조사 3가 그룹 B 연쇄상구균 다당류 CRM 197 -임신 중 접합 백신을 받은 여성에게서 태어난 영아의 항체 동역학 및 정기 예방 접종에 대한 반응Articles and Commentaries Published on 2017-12-012022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, 백일해, 파상풍, [키워드] age antenatal vaccination antibody antibody level antibody levels Birth capsular clinical clinically Combination detectable Diphtheria diphtheria toxoid disease dosage dosages dose during pregnancy elicited enrolled geometric mean geometric mean concentration group group B Streptococcus conjugate vaccine groups Haemophilus influenzae Haemophilus influenzae type b immune response immune responses Infant Infants invasive investigated Kinetics Maternal mother not affect pediatric Placebo placebo group pneumococcal pneumococcal vaccination Pregnancy Randomized receive Received recipients Registration response Result routine routine immunization serotype serotype-specific serotypes significantly higher single-center study Streptococcus Tetanus the placebo group timepoint transferred trivalent vaccination Vaccine were assessed women [DOI] 10.1093/cid/cix666 PMC 바로가기 [Article Type] Articles and Commentaries